Travel Vaccines
SKU
MRR-0316851957A3
Region
Global
Publication Date
February 2024
Delivery
Immediate
2022
USD 7.52 billion
2030
USD 16.18 billion
2023
USD 8.26 billion
CAGR
10.04%
Travel Vaccines Market by Type (Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines), Disease (DPT, Hepatitis A, Hepatitis B) - Global Forecast 2023-2030

[191 Pages Report] The Travel Vaccines Market size was estimated at USD 7.52 billion in 2022 and expected to reach USD 8.26 billion in 2023, at a CAGR 10.04% to reach USD 16.18 billion by 2030.

Travel Vaccines Market
To learn more about this report, request a free sample copy

The travel vaccines market encompasses the production, distribution, and administration of immunizations recommended or required for international travelers based on specific regional disease risk exposures. The ongoing growth in the travel vaccines market is primarily driven by increased international travel, rising awareness about vaccine-preventable diseases, and governmental travel regulations mandating certain vaccines for entry. Additionally, the expansion of the global tourism industry and proactive health measures by international travelers fuel the demand for travel vaccines. Technological advancements in vaccine storage and stability contribute to market growth by enabling wider vaccine accessibility and distribution. The major challenges affecting the growth of the travel vaccines market include high costs associated with vaccine development and strict regulatory requirements leading to prolonged approval times. Additionally, the limited shelf life of vaccines, cold chain logistics requirements, and vaccine hesitancy among specific traveler demographics further impede market growth. Emerging market opportunities include developing vaccines against evolving infectious disease threats and expanding the existing travel vaccine portfolio to include neglected tropical diseases. An increase in public-private partnerships for vaccine research and development and the incorporation of digital health technologies for personalized travel health advisories and vaccine reminders represent significant prospects for industry expansion.

Travel Vaccines Market - Global Forecast 2023-2030
To learn more about this report, request a free sample copy
Type: Advancements in DNA vaccines to induce immune response

Attenuated vaccines utilize a weakened form of the germ that causes a disease. Attenuated vaccines are highly effective in eliciting strong and long-lasting immune responses. Conjugate vaccines are designed to combat bacteria with polysaccharide outer coatings. By linking antigens or toxoids from a microbe that the immune system can recognize to the polysaccharides, conjugate vaccines improve the body's immune response to the bacterium. DNA vaccines represent a cutting-edge approach by directly injecting genetically engineered DNA so cells can produce an antigen and induce an immune response. Inactive vaccines use the killed version of the germ that causes a disease and are safer than live vaccines, especially for people with weakened immune systems, but may require multiple doses to maintain immunity. Recombinant vector vaccines use a virus or a bacterium to introduce microbial DNA to body cells and are sophisticated in design and capable of inducing strong immune responses. Subunit vaccines include only the essential antigens and not all other molecules of the microbe and have a lower risk of side effects but may require adjuvants to enhance the immune response. Toxoid vaccines are used against bacteria that produce toxins in the body and are made by inactivating the toxins produced by the bacteria, which in turn induces an immune response.

Disease: Need based preference for hepatitis vaccines among travelers

DPT vaccines are primarily recommended for young children, but booster shots are advised for adults traveling to areas where diphtheria and pertussis (whooping cough) are still prevalent. Hepatitis is recommended for most travelers, especially those visiting regions with higher rates of Hepatitis A infection such as Asia, Africa, and Central and South America. Japanese encephalitis is advised for travelers staying for extended periods in endemic areas, especially in rural Asia. The meningococcal vaccine is essential for travelers to sub-Saharan Africa during the dry season and for pilgrims to the Hajj in Saudi Arabia. Rabies vaccine is recommended for travelers involved in outdoor activities in areas where rabies is a risk or for those traveling to remote locations where medical care is difficult to access. Varicella (Chickenpox) is essential for non-immune travelers, particularly young adults and healthcare professionals. Yellow fever is critical for travelers to endemic regions in Africa and South America.

Regional Insights

In the Americas, the United States and Canada represent significant markets for travel vaccines, driven by high outbound travel rates and robust healthcare infrastructure. Consumer behavior shows a high degree of awareness and preparedness for travel health, leading to a steadfast demand for vaccines against diseases such as Yellow Fever, Typhoid, and Hepatitis A and B. The European Union exhibits a robust travel vaccine market due to well-established healthcare systems and high travel frequency to regions with vaccine-preventable diseases. The EU's streamlined regulatory framework fosters a conducive environment for introducing new vaccines. The Middle East & Africa region presents a varied landscape for travel vaccines, with the Gulf Cooperation Council countries showing growing demand due to increasing travel and healthcare investments. The Asia Pacific region is witnessing rapid growth in the travel vaccine market, with China, Japan, and India leading the way for market expansion. Notably, China and India invest heavily in vaccine R&D to become self-sufficient in vaccine production. Japan's market is distinguished by high consumer awareness and advanced vaccine technology, supported by government-led immunization campaigns.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Travel Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Travel Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad

    The Indian Immunologicals Limited (IIL) has launched Havisure, the nation’s first indigenously developed vaccine against Hepatitis A. This highly contagious liver infection, primarily transmitted through the fecal-oral route via contaminated food or water, represents a substantial public health concern. Through rigorous clinical testing across eight centers, Havisure has demonstrated its safety and efficacy, showcasing results on par with the leading global vaccines [Published On: 2024-01-20]

  • FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

    Pfizer Inc. has achieved a significant milestone in public health with the U.S. Food and Drug Administration (FDA)'s approval of PENBRAYA, the inaugural pentavalent vaccine offering comprehensive protection against the predominant serogroups (A, B, C, W, and Y) responsible for causing meningococcal disease among adolescents and young adults aged 10 through 25. This innovative vaccine merges the strengths of Trumenba and Nimenrix, targeting the five key serogroups linked to the majority of invasive meningococcal disease (IMD) instances globally. [Published On: 2023-10-20]

  • Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

    Pfizer Inc. and BioNTech SE have announced the approval from the U.S. Food and Drug Administration (FDA) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine, tailored for the 2023-2024 flu season. This approval encompasses a supplemental Biologics License for those aged 12 and older, alongside an emergency use authorization for ages 6 months to 11 years. This updated vaccine, recommended for a single dose in individuals 5 years and up—with particular dosing guidelines for children under 5—aims to fortify protection against the evolving COVID-19 variants, especially the predominant Omicron XBB-related sublineages. [Published On: 2023-09-11]

Key Company Profiles

The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, Biological E Limited, Cadila Pharmaceuticals Limited, CSL Limited, Dano Vaccines & Biologicals Private Limited, Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Indian Immunologicals Ltd., Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Attenuated Vaccines
    • Conjugate Vaccines
    • DNA Vaccines
    • Inactive Vaccines
    • Recombinant Vector Vaccines
    • Subunit Vaccines
    • Toxoid Vaccines
  • Disease
    • DPT
    • Hepatitis A
    • Hepatitis B
    • Japanese Encephalitis
    • Measles and Mumps
    • Meningococcal
    • Rabies
    • Typhoid
    • Varicella
    • Yellow Fever

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Travel Vaccines Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Travel Vaccines Market?
  3. What are the technology trends and regulatory frameworks in the Travel Vaccines Market?
  4. What is the market share of the leading vendors in the Travel Vaccines Market?
  5. Which modes and strategic moves are suitable for entering the Travel Vaccines Market?

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & CoverageTRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
    3. Years Considered for the Study
    4. Currency & PricingUNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
    5. Language
    6. Limitations
    7. Assumptions
    8. Stakeholders
  2. Research Methodology
    1. TRAVEL VACCINES MARKET RESEARCH PROCESS
    2. Define: Research Objective
    3. Determine: Research Design
    4. Prepare: Research Instrument
    5. Collect: Data Source
    6. Analyze: Data Interpretation
    7. Formulate: Data Verification
    8. Publish: Research Report
    9. Repeat: Report Update
  3. Executive Summary
    1. TRAVEL VACCINES MARKET SIZE, 2022 VS 2030
  4. Market Overview
    1. IntroductionTRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
    2. Travel Vaccines Market, by RegionTRAVEL VACCINES MARKET SIZE, BY REGION, 2022 VS 2030 (%)TRAVEL VACCINES MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  5. Market Insights
    1. Market DynamicsTRAVEL VACCINES MARKET DYNAMICS
      1. Drivers
        1. Increasing Popularity of International Tourism
        2. Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
        3. Recent Investments and Improvement in Cold Chain Storage Infrastructure
      2. Restraints
        1. Limited Awareness Amongst Travelers
      3. Opportunities
        1. Innovations in Novel Vaccine Technologies and Advancements
        2. Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
      4. Challenges
        1. Issues Related to Vaccine Handling and Storage
    2. Market Segmentation Analysis
      1. Type: Advancements in DNA vaccines to induce immune response
      2. Disease: Need based preference for hepatitis vaccines among travelers
    3. Market Trend Analysis
    4. Cumulative Impact of COVID-19
    5. Cumulative Impact of Russia-Ukraine Conflict
    6. Cumulative Impact of High Inflation
    7. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    8. Value Chain & Critical Path Analysis
    9. Regulatory Framework
    10. Client Customization
  6. Travel Vaccines Market, by Type
    1. IntroductionTRAVEL VACCINES MARKET SIZE, BY TYPE, 2022 VS 2030 (%)TRAVEL VACCINES MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
    2. Attenuated VaccinesTRAVEL VACCINES MARKET SIZE, BY ATTENUATED VACCINES, BY , 2018-2030 (USD MILLION)
    3. Conjugate VaccinesTRAVEL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY , 2018-2030 (USD MILLION)
    4. DNA VaccinesTRAVEL VACCINES MARKET SIZE, BY DNA VACCINES, BY , 2018-2030 (USD MILLION)
    5. Inactive VaccinesTRAVEL VACCINES MARKET SIZE, BY INACTIVE VACCINES, BY , 2018-2030 (USD MILLION)
    6. Recombinant Vector VaccinesTRAVEL VACCINES MARKET SIZE, BY RECOMBINANT VECTOR VACCINES, BY , 2018-2030 (USD MILLION)
    7. Subunit VaccinesTRAVEL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY , 2018-2030 (USD MILLION)
    8. Toxoid VaccinesTRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY , 2018-2030 (USD MILLION)
  7. Travel Vaccines Market, by Disease
    1. IntroductionTRAVEL VACCINES MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    2. DPTTRAVEL VACCINES MARKET SIZE, BY DPT, BY , 2018-2030 (USD MILLION)
    3. Hepatitis ATRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY , 2018-2030 (USD MILLION)
    4. Hepatitis BTRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY , 2018-2030 (USD MILLION)
    5. Japanese EncephalitisTRAVEL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY , 2018-2030 (USD MILLION)
    6. Measles and MumpsTRAVEL VACCINES MARKET SIZE, BY MEASLES AND MUMPS, BY , 2018-2030 (USD MILLION)
    7. MeningococcalTRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY , 2018-2030 (USD MILLION)
    8. RabiesTRAVEL VACCINES MARKET SIZE, BY RABIES, BY , 2018-2030 (USD MILLION)
    9. TyphoidTRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY , 2018-2030 (USD MILLION)
    10. VaricellaTRAVEL VACCINES MARKET SIZE, BY VARICELLA, BY , 2018-2030 (USD MILLION)
    11. Yellow FeverTRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY , 2018-2030 (USD MILLION)
  8. Americas Travel Vaccines Market
    1. Introduction
    2. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)AMERICAS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    3. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Argentina
    5. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ARGENTINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    6. Brazil
    7. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)BRAZIL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    8. Canada
    9. CANADA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)CANADA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    10. Mexico
    11. MEXICO TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)MEXICO TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    12. United States
    13. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED STATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    14. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2022 VS 2030 (%)UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  9. Asia-Pacific Travel Vaccines Market
    1. Introduction
    2. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    3. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Australia
    5. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    6. China
    7. CHINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)CHINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    8. India
    9. INDIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)INDIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    10. Indonesia
    11. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)INDONESIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    12. Japan
    13. JAPAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)JAPAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    14. Malaysia
    15. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)MALAYSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    16. Philippines
    17. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    18. Singapore
    19. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SINGAPORE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    20. South Korea
    21. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    22. Taiwan
    23. TAIWAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)TAIWAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    24. Thailand
    25. THAILAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)THAILAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    26. Vietnam
    27. VIETNAM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)VIETNAM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  10. Europe, Middle East & Africa Travel Vaccines Market
    1. Introduction
    2. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    3. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Denmark
    5. DENMARK TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)DENMARK TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    6. Egypt
    7. EGYPT TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)EGYPT TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    8. Finland
    9. FINLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)FINLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    10. France
    11. FRANCE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)FRANCE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    12. Germany
    13. GERMANY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)GERMANY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    14. Israel
    15. ISRAEL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ISRAEL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    16. Italy
    17. ITALY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ITALY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    18. Netherlands
    19. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    20. Nigeria
    21. NIGERIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NIGERIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    22. Norway
    23. NORWAY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NORWAY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    24. Poland
    25. POLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)POLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    26. Qatar
    27. QATAR TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)QATAR TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    28. Russia
    29. RUSSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)RUSSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    30. Saudi Arabia
    31. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    32. South Africa
    33. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    34. Spain
    35. SPAIN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SPAIN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    36. Sweden
    37. SWEDEN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SWEDEN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    38. Switzerland
    39. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    40. Turkey
    41. TURKEY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)TURKEY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    42. United Arab Emirates
    43. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
    44. United Kingdom
    45. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  11. Competitive Landscape
    1. FPNV Positioning MatrixTRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2022TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2022
    2. Market Share Analysis, By Key PlayerTRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2022TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2022
    3. Competitive Scenario Analysis, By Key Player
      1. India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad
      2. FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
      3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
  12. Competitive Portfolio
    1. Key Company Profiles
      1. Abbott Laboratories
      2. AstraZeneca PLC
      3. Bavarian Nordic A/S
      4. Bharat Biotech Ltd.
      5. Bio-Manguinhos
      6. Bio-Med (P) Limited
      7. Biological E Limited
      8. Cadila Pharmaceuticals Limited
      9. CSL Limited
      10. Dano Vaccines & Biologicals Private Limited
      11. Dynavax Technologies Corporation
      12. Emergent BioSolutions Inc.
      13. GlaxoSmithKline PLC
      14. Incepta Pharmaceuticals Ltd.
      15. Indian Immunologicals Ltd.
      16. Johnson & Johnson Services, Inc
      17. Merck & Co., Inc.
      18. Novartis AG
      19. Pfizer Inc.
      20. Sanofi S.A.
      21. Serum Institute of India Pvt. Ltd.
      22. Shenzhen Kangtai Biological Products Co., Ltd.
      23. Takeda Pharmaceutical Company Limited
      24. Valneva SE
      25. Walvax Biotechnology Co., Ltd.
    2. Key Product Portfolio
  1. Abbott Laboratories
  2. AstraZeneca PLC
  3. Bavarian Nordic A/S
  4. Bharat Biotech Ltd.
  5. Bio-Manguinhos
  6. Bio-Med (P) Limited
  7. Biological E Limited
  8. Cadila Pharmaceuticals Limited
  9. CSL Limited
  10. Dano Vaccines & Biologicals Private Limited
  11. Dynavax Technologies Corporation
  12. Emergent BioSolutions Inc.
  13. GlaxoSmithKline PLC
  14. Incepta Pharmaceuticals Ltd.
  15. Indian Immunologicals Ltd.
  16. Johnson & Johnson Services, Inc
  17. Merck & Co., Inc.
  18. Novartis AG
  19. Pfizer Inc.
  20. Sanofi S.A.
  21. Serum Institute of India Pvt. Ltd.
  22. Shenzhen Kangtai Biological Products Co., Ltd.
  23. Takeda Pharmaceutical Company Limited
  24. Valneva SE
  25. Walvax Biotechnology Co., Ltd.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Travel Vaccines Market
The Global Travel Vaccines Market size was estimated at USD 7.52 billion in 2022 and expected to reach USD 8.26 billion in 2023.
The Global Travel Vaccines Market to grow USD 16.18 billion by 2030, at a CAGR of 10.04%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.